ONCY
ONCOLYTICS BIOTECH INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 11 to Feb 12 ▲ 2 days of insider buys: $243.7K by 9 insiders, avg $0.8426
- Mar 11 to Mar 12 ▲ 2 days of insider buys: $15.1K by 2 insiders, avg $1.01
- Sep 10 FDA: Oncolytics Biotech® Announces Positive Preclinical Results…
- Oct 20 FDA: Oncolytics Biotech® to Present REO 033 Trial in Progress A…
- Oct 27 ▲ Oncolytics Biotech announced updated data from Cohort 4 of the GOBLE…
- Oct 27 ▲ Oncolytics Biotech announced updated data from Cohort 4 of its Phase…
- Oct 27 FDA: Oncolytics Biotech® Reports Strong Durability and Survival…
- Nov 4 ▲ Oncolytics Biotech presented new translational data at SITC 2026 sho…
- Nov 4 FDA: Translational Data from Anal Cancer Patients Show Pelareor…
- Nov 9 FDA: Pelareorep Induces Coordinated Antiviral Immune Responses…
- Nov 11 Contract: Oncolytics Biotech® Announces Clinical Supply Agreement to…
- Nov 13 Contract: Oncolytics Biotech® Announces Clinical Supply Agreement to…
Signal stack
Where each data set points today.
- InsidersBULLISH
10 insiders bought $258.8K at an average $0.8507. No open-market sales. Price is 60% below their cost.
- InstitutionsMIXED
Q3 2026: 5 added (0 new), 5 trimmed or exited.
- AnalystsBULLISH
6 of 8 rate it Buy or better.
- EstimatesFALLING
Current-quarter EPS estimate −$0.080 → −$0.085 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −3.8% to 8.68M shares. 9.9 days to cover, ≈6.6% of shares.
- TrendDOWNTREND
40% below its 50-day average. New closing low $0.3400 on Nov 16.
- SocialQUIET
Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Invesco Ltd. | ADD | $95.0K |
| CITIGROUP INC | DOUBLED | $81.2K |
| FIFTH THIRD BANCORP | ADD | $57.1K |
| HRT FINANCIAL LP | TRIM | $24.0K |
| UBS Group AG | TRIM | $11.0K |
| TD Waterhouse Canada Inc. | TRIM | $291.00 |
| NewEdge Advisors, LLC | DOUBLED | $200.00 |
| JPMORGAN CHASE & CO | NEAR_EXIT | $24.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analysts| Date | Firm | Rating |
|---|---|---|
| Aug 19, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| May 26, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brown Deborah Margaret Director Jun 1, 2026 | AWARD | 30,000 sh |
Andrews Patricia S Director Jun 1, 2026 | AWARD | 30,000 sh |
Holtham Angela Director Jun 1, 2026 | AWARD | 30,000 sh |
Glover Stephen C. Director Jun 1, 2026 | AWARD | 96,000 sh |
Heineman Thomas Charles Chief Medical Officer Jun 1, 2026 | AWARD | 260,000 sh |
Seizinger Bernd R. Director Jun 1, 2026 | AWARD | 30,000 sh |
Parsons James T. Director Jun 1, 2026 | AWARD | 30,000 sh |
Hagerman Allison Chief Technology Officer Jun 1, 2026 | AWARD | 260,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.08 | -$0.09–-$0.08 | -1.4% | $0.00 |
| Next Q | -$0.06 | -$0.07–-$0.06 | +7.7% | $0.00 |
| Current FY | -$0.38 | -$0.39–-$0.37 | -0.1% | $0.00 |
| Next FY | -$0.28 | -$0.28–-$0.23 | +3.4% | $0.00 |
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
25 filings · 7 press releases · 7 bullish · 3 bearish · 15 neutral- NEUTRAL PRESS RELEASENov 13, 2026
Oncolytics Biotech entered a clinical supply agreement with Coherus Oncology to evaluate its…
The agreement provides pelareorep access to a marketed PD-1 inhibitor without upfront cost, but the study is early-stage (Phase 2, single indication) and results are at least 12-18 months away…
- NEUTRAL 8-KNov 12, 2026
Oncolytics Biotech announced a clinical supply agreement with Coherus Oncology to evaluate its…
The agreement is a low-cost, non-dilutive way to generate early combination data in an indication with no approved second-line therapy. However, the study is exploratory, small-scale, and not…
- NEUTRAL PRESS RELEASENov 11, 2026
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate its…
Monitor for study initiation in Q1 2027 and any interim data readouts. The collaboration validates pelareorep's potential in HPV-associated cancers but provides no near-term revenue. Success could…
- NEUTRAL 8-KNov 9, 2026
Oncolytics Biotech issued a press release announcing translational data from a Phase 1b/2 trial of…
The translational data provide mechanistic support for pelareorep in hematological cancers but lack clinical response rates or survival data. Watch for the full ASH presentation on December 12, 2026…
All ONCY filing & press-release reports (32)
- PRESS-RELEASE reportNov 13, 2026
- 8-K reportNov 12, 2026
- PRESS-RELEASE reportNov 11, 2026
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportOct 27, 2026
- PRESS-RELEASE reportOct 27, 2026
- 8-K reportOct 20, 2026
- PRESS-RELEASE reportOct 20, 2026
- 8-K reportOct 14, 2026
- 8-K reportOct 13, 2026
- DEFA14A reportOct 6, 2026
- DEF 14A reportOct 6, 2026
- 8-K reportSep 29, 2026
- 8-K reportSep 28, 2026
- 8-K reportSep 10, 2026
- 8-K reportJul 20, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 16, 2026
- 8-K reportJun 2, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 22, 2026
- PRESS-RELEASE reportMay 22, 2026
- 8-K reportApr 27, 2026
- 424B5 reportApr 6, 2026
- 8-K reportApr 6, 2026
- EFFECT reportApr 6, 2026
- S-3 reportMar 31, 2026
- CLUSTER reportMar 11, 2026
- 8-K reportFeb 24, 2026